Fida Biosystems offers a new proprietary technology developed for quantification and characterization of proteins and nanoparticles from 0.5 to 1,000 nm Dh, incl. antibodies, liposomes, exosomes, membrane embedded proteins et al. Based on accurate, in-solution, absolute measurements of hydrodynamic radius, the technology provides precise information about Kd, concentration, size, stoichiometry, conformational changes, oligomeric state, immunogenicity, multiple bindings etc. It is characterised by being fast (minutes), requiring very small sample amounts (ul-nl), and being exceptionally tolerant to the sample matrix, incl. plasma, serum, cell lysate, fermentation media etc. Contrary to most other procedures, the methodology is based on binding in homogenous solution; complications related to non-specific surface adsorption and challenging assay development are therefore avoided.   I.e. the unique features of the FIDA technology enable characterisation and quantification in native (biorelevant) environments and in-built assay quality control and automation.

Biotechnology

Health Care

Fida Biosystems

Brian Sørensen

Philipp W.

Jan Gøral

Emil Georg Palmkvist Vangsgaard Stender

Dr. Rer. Nat. Kritika Sahni Ray

Adam Coln Hundahl

Maja Wasilczyk

Cameron Parast

Henrik Jensen

Hasse Hedeby

The Leadership Team at Fida Biosystems, consisting of the CEO, Chief Commercial Officer (CCO), and Chief Scientific Officer (CSO), is responsible for setting the strategic direction, driving commercial success, and overseeing scientific innovations. They ensure alignment of company goals with market needs, manage key business operations, foster partnerships, secure funding, and guide research and development to maintain Fida Biosystems' competitive edge in protein and nanoparticle characterization technology.

Leadership Team

Business Development

Application and Laboratory Scientists

Leadership Team

About

Team members

Other teams at Fida Biosystems

Business Development

Application and Laboratory Scientists